Class Eligibility

You are a class member if you urchased and/or paid for Aggrenox® or generic versions of Aggrenox®, in the Commonwealth of Puerto Rico, Arizona, California, Colorado, District of Columbia, Florida, Hawaii, Illinois, Iowa, Kansas, Maine, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Nebraska, Nevada, New Hampshire, New Mexico, New York, North Carolina, North Dakota, Oregon (2010 or after), Rhode Island (purchases after July 15, 2013), South Dakota, Tennessee, Utah, Vermont, West Virginia, and Wisconsin for consumption by yourself or your family, from November 30, 2009 through December 22, 2017.

Estimated Amount

Varies

This is a pro rata settlement. Once the expenses and attorney’s fees are paid the net settlement will be divided among the valid claims

Proof of Purchase

No

Case Name

In re: Aggrenox® Antitrust Litigation,
Case No. 3:14-md-02516-SRU
District Court for the District of Connecticut

Case Summary

he lawsuit is about the price of Aggrenox and whether its manufacturer, Boehringer Ingelheim, delayed the availability of an allegedly less-expensive generic version through alleged anticompetitive agreements with Barr. Plaintiffs (those who brought the suit) allege that Boehringer Ingelheim and Barr did so through unlawful settlement of patent lawsuits in which the patents covering Aggrenox were in dispute. After the challenged agreements were entered into, Barr was acquired by Teva. Plaintiffs claim that Defendants’ actions denied Indirect Purchasers who paid for Aggrenox the benefits of competition and caused them to pay higher prices for Aggrenox than they otherwise would have paid.

Defendants deny these claims and deny that they did anything wrong. Defendants assert that the settlement of the patent lawsuits did not violate Federal or state antitrust or consumer protection laws. Defendants assert that their conduct has not delayed the entry of generic versions of Aggrenox into the market. No court or other authority has found that Defendants engaged in any wrongdoing.

Settlement Pool

$54,000,000

Deadline

09/14/2018

Contact


Aggrenox Settlement
c/o A.B. Data, Ltd.
P.O. Box 173046
Milwaukee, WI 53217
P:800-494-2165
info@InReAggrenoxAntitrustLitigation.com

6 responses to “Aggrenox Generic Drug Delay Class Action Settlement”

  1. Dale Chester says:

    I think I used this after having a stroke during 2014 or so. Or a generic of it..

    ADMIN – Hi Dale,

    If you used the real thing you are a class member.

  2. Shirley Reid-Cobb says:

    I have used Aggrenox for many years. How can I join the class action?

    ADMIN – Hi Shirley,

    Click on the link that reads file a claim and complete the forms as applicable.

  3. Ruth Smith says:

    I have been on aggranox for four years and have paid full price for it before and with insurance it is expensive. When in donut hole with medicare I paid out of pocket
    Please add me to the suit.

    ADMIN – Hi Ruth,

    I can’t add you. You must complete the claim form yourself.

  4. William McDaniel says:

    I have purchased the medication 15 times and the cost was 360.00 each purchase.

    ADMIN – Hi William,

    It sounds like you are a member of the class.

  5. Kimberly says:

    I used this and did not like it at all

    ADMIN – Hi Kimberly,

    This settlement is not about you liking the product or not. It is about delayed release of generic versions.

  6. pwnxx595@hotmail.com says:

    I never actually used Aggrenox but thought about taking it. Am I still eligible to make a claim?

    ADMIN – Hi P,

    NO

Leave a Reply

Your email address will not be published. Required fields are marked *